[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Azienda Ospedaliera \\\"Sant'Andrea\\\"\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":107},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100615361","microplastics-and-nanoplastics-in-patients-with-chronic-coronary-syndromes-100615361",false,"NCT07291609","Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes","CCS-Plastics","Inclusion Criteria:\n\nALL the following:\n\n1. Age \\> 18 years old;\n2. Suspected or known chronic coronary syndromes undergoing coronary CT angiography;\n3. Clinical indication to invasive coronary angiography;\n4. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Coronary CT angiography not available;\n2. Poor quality CCTA;\n3. Absence of native coronary stenosis \\>=50% at CCTA;\n4. Contraindications to invasive coronary angiography and percutaneous coronary intervention\n5. Life expectancy \\\u003C 1 year due to non-cardiac pathology","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","3 Years","OBSERVATIONAL","The CCS-plastics is an investigator-initiated, prospective, multicenter study of patients undergoing coronary CT angiography (CCTA) for suspected or known chronic coronary syndromes (CCS) referred to invasive coronary angiography for clinical indication. Patients identified as eligible for the protocol will be asked for written consent to participate in the study. The patients' dossiers will be uploaded and transmitted to the core laboratory for analysis. The routine management of the CCS patients will not be affected and all patients will be managed according to current standards. Invasive coronary angiography and coronary blood samples will be performed following the current standards, guidelines, and indications. During invasive coronary angiography, coronary blood samples will be collected per standard of care and sent to a centralized, specialized core laboratory for MNPs and biomarkers analysis. The central core lab for MNPs analyses will be the University of Campania Luigi Vanvitelli, Naples, Italy. The identification, quantification (concentration, mcg\u002Fml), and typing of plastic particles will be performed in each tube for each patient, using pyrolysis-gas chromatography-mass spectrometry (Py-GC\u002FMS) and laser direct infrared (LDIR) spectroscopy. The CCTA will be centrally analyzed by Centro Cardiologico Monzino to evaluate qualitative and quantitative plaque features. Patients will be followed clinically at 1 and 3 years per standard of care.",[25,26,27,28,29,30,31],"Chronic Coronary Syndrome","Microplastics","Nanoplastics","Coronary Artery Disease","Coronary Plaque","Computed Tomography","Pollution Exposure","RECRUITING","2026-06-06",{"date":35,"type":36},"2026-06-09","ACTUAL",{"date":38,"type":36},"2025-01-01",{"date":40,"type":20},"2029-12-31",{"name":42,"class":43},"Azienda Ospedaliera \"Sant'Andrea\"","OTHER",6,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100638082","derivation-and-validation-of-the-aortic-valve-echocardiographic-calcium-score-to-confirm-severe-aortic-stenosis-the-echo-avcs-study-100638082","NCT07620925","Derivation and Validation of the Aortic Valve Echocardiographic Calcium Score to Confirm Severe Aortic Stenosis: the Echo-AVCS Study","Echo-AVCS","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Clinical indication for standard transthoracic echocardiography.\n* Clinical indication for cardiac CT with available calcium score.\n* 3-month time interval between transthoracic echocardiography and cardiac CT.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Patients with inadequate transthoracic echocardiographic images.\n* Poor quality cardiac CT, inadequate for standard calcium score assessment.\n* Patients with known prior stents and\u002For coronary artery bypass grafts.\n* Patients with known previous percutaneous or surgical aortic valve replacement.\n* Patients with active or a history of endocarditis.\n* Patients with congenital heart defects (other than isolated bicuspid aortic valve).",{"count":53,"type":20},250,"1 Year","The Echo-AVCS Study is an investigator-initiated, prospective, multicenter observational study designed to derive and validate an artificial intelligence (AI)-based echocardiographic aortic valve calcium score (Echo-AVCS) for confirming severe aortic stenosis (AS). Transthoracic echocardiography (TTE) is the standard imaging modality for assessing AS severity; however, discrepancies between valve area and transvalvular gradient measurements may complicate diagnosis, particularly in low-flow or discordant AS presentations. Cardiac computed tomography (CT)-derived aortic valve calcium scoring is currently used to resolve diagnostic uncertainty, but it involves additional cost and radiation exposure. This study will enroll consecutive adult patients undergoing clinically indicated TTE and cardiac CT with calcium scoring performed within 3 months. Standardized echocardiographic images will be centrally analyzed using dedicated AI-based image segmentation and machine learning methods to quantify aortic valve calcification directly from TTE images. CT-derived aortic valve calcium score will serve as the reference standard. The primary objective is to derive and validate the Echo-AVCS score for identifying severe AS. Secondary objectives include determination of sex-specific diagnostic thresholds, correlation with CT calcium volume, association with symptoms and NYHA class, and evaluation of prognostic associations with aortic valve replacement, heart failure hospitalization, cardiovascular events, and mortality at 1-year follow-up.",[57,25,58,59],"Aortic Stenosis","Calcific Aortic Valve Disease","Calcific Aortic Stenosis",[61,62,63,64,65],"Aortic stenosis","Low-flow","Aortic valve calcium score","Echocardiography","Cardiac-CT","2026-06-03",{"date":68,"type":36},"2026-06-04",{"date":70,"type":36},"2026-03-01",{"date":72,"type":20},"2027-12-31",{"name":42,"class":43},5,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":105,"locationsCount":106},"100590254","microplastics-and-nanoplastics-mnps-in-patients-with-st-elevation-myocardial-infarction-stemi-100590254","NCT06965023","Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)","STEMI-Plastics","Inclusion Criteria:\n\nAll the following inclusion criteria should be fulfilled:\n\n1. Age \\> 18 years old;\n2. STEMI undergoing urgent invasive coronary angiography;\n3. Acute thrombotic coronary occlusion\u002Fsub-occlusion (TIMI 0\u002F1);\n4. Clinical indication to thromboaspiration;\n5. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to percutaneous coronary intervention;\n2. Hemodynamic instability or cardiogenic shock;\n3. End-stage chronic kidney disease;\n4. Life expectancy \\\u003C 1 year due to non-cardiac pathology.",{"count":83,"type":20},130,"Air pollution and microplastics pose major public health threats. Emerging data have shown that micro- and nanoplastics (MNPs) are ubiquitous environmental pollutants accumulating in human tissues, triggering inflammation and prothrombotic state. This study will investigate the presence and burden of MNPs within coronary thrombi\u002Fthromboaspirate of patients presenting with ST segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention and their association with cardiac damage, plaque vulnerability, microvascular obstruction, and cardiovascular events. Plaque vulnerability will be explored by optical coherence tomography, while microvascular obstruction will be assessed by bolus thermodilution and cardiac magnetic resonance. Participants will be followed up for 1-year to evaluate whether the presence and the burden of MNPs will be associated with a higher incidence of the cardiovascular events.",[86,26,27,31],"ST-elevation Myocardial Infarction (STEMI)",[88,26,27,89,90,91,92,93,94,95,96,97,98],"STEMI","Inflammation","OCT","Plaque composition","cardiac magnetic resonance","Pollution","Exposome","Infarct Size","Coronary Microvascular Dysfunction","IMR","MRR","2025-05-01",{"date":101,"type":36},"2025-05-11",{"date":103,"type":36},"2025-04-22",{"date":72,"type":20},{"name":42,"class":43},10,""]